Opioid Suits May Reduce Appetite for Pharma Companies -- ESG Insight
May 28 2019 - 12:23PM
Dow Jones News
11:53 ET - ESG investors may choose to avoid companies for their
alleged roles tied to the opioid crisis in the US. This week's
trial against Johnson & Johnson, which Purdue Pharma and Teva
Pharmaceuticals agreed to settle, is one of 2,000 lawsuits lined up
against drug makers, retailers and distributors of opioids. The
claims involve aggressive and irresponsible marketing, as well as
the spreading of misinformation regarding their drugs. These social
factors may make these companies look less attractive to ESG
investors. For activist investors, these suits could provide an
opportunity to push for company-level changes aligned with their
investment views. (christian.brunnstrom@dowjones.com)
(END) Dow Jones Newswires
May 28, 2019 12:08 ET (16:08 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024
